Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart has believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its development programs currently include tablet vaccines designed to protect against coronavirus, Norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immuno-oncology indication. Vaxart has filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Company profile
Ticker
VXRT
Exchange
Website
CEO
Andrei Floroiu
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Exelixis • Ginkgo Bioworks ...
Former names
Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., NABI BIOPHARMACEUTICALS, NABI /DE/, NABI BIOPHARMACEUTICALS, NORTH AMERICAN BIOLOGICALS INC
SEC CIK
Corporate docs
Subsidiaries
Vaxart Biosciences, Inc. • Biota Holdings • Biota Scientific Management Pty, Ltd. ...
IRS number
591212264
VXRT stock data
Latest filings (excl ownership)
S-3
Shelf registration
17 Mar 23
8-K
Vaxart Provides Business Update and Full Year 2022 Financial Results
15 Mar 23
10-K
2022 FY
Annual report
15 Mar 23
8-K
Vaxart Names Phillip Lee as Chief Financial Officer
19 Dec 22
8-K
Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers
6 Dec 22
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results
8 Nov 22
S-8
Registration of securities for employees
21 Oct 22
8-K
Regulation FD Disclosure
1 Sep 22
8-K
Vaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D. Joins Board of Directors
25 Aug 22
Latest ownership filings
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 46.01 mm | 46.01 mm | 46.01 mm | 46.01 mm | 46.01 mm | 46.01 mm |
| Cash burn (monthly) | 1.59 mm | 8.14 mm | 10.38 mm | 9.59 mm | 9.72 mm | 7.90 mm |
| Cash used (since last report) | 4.69 mm | 24.09 mm | 30.71 mm | 28.37 mm | 28.75 mm | 23.37 mm |
| Cash remaining | 41.32 mm | 21.92 mm | 15.31 mm | 17.65 mm | 17.27 mm | 22.65 mm |
| Runway (months of cash) | 26.1 | 2.7 | 1.5 | 1.8 | 1.8 | 2.9 |
Institutional ownership, Q4 2022
32.7% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 129 |
| Opened positions | 22 |
| Closed positions | 32 |
| Increased positions | 38 |
| Reduced positions | 37 |
| 13F shares | Current |
|---|---|
| Total value | 41.95 bn |
| Total shares | 44.32 mm |
| Total puts | 55.40 k |
| Total calls | 620.60 k |
| Total put/call ratio | 0.1 |
| Largest owners | Shares | Value |
|---|---|---|
| BLK Blackrock | 8.86 mm | $8.51 bn |
| Vanguard | 7.02 mm | $6.75 bn |
| Two Sigma Investments | 2.63 mm | $2.53 bn |
| Geode Capital Management | 2.58 mm | $2.49 bn |
| Citadel Advisors | 2.44 mm | $2.34 bn |
| STT State Street | 2.40 mm | $2.30 bn |
| Two Sigma Advisers | 2.06 mm | $1.98 bn |
| Millennium Management | 1.69 mm | $1.64 bn |
| D. E. Shaw & Co. | 1.23 mm | $1.18 bn |
| NTRS Northern Trust | 1.08 mm | $1.04 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 17 Mar 33 | Phillip E Lee | Stock Option Common Stock | Grant | Acquire A | No | No | 0.78 | 410,000 | 319.80 k | 410,000 |
| 17 Mar 23 | Tucker Sean | Common Stock | Grant | Acquire A | No | No | 0 | 90,000 | 0.00 | 316,788 |
| 17 Mar 23 | Tucker Sean | Common Stock | Grant | Acquire A | No | No | 0 | 54,157 | 0.00 | 226,788 |
| 17 Mar 23 | Tucker Sean | Common Stock | Grant | Acquire A | No | No | 0 | 45,000 | 0.00 | 172,631 |
| 17 Mar 23 | Tucker Sean | Stock Option Common Stock | Grant | Acquire A | No | No | 0.78 | 410,000 | 319.80 k | 410,000 |
| 17 Mar 23 | Tucker Sean | Stock Option Common Stock | Grant | Acquire A | No | No | 0.78 | 205,000 | 159.90 k | 205,000 |
| 17 Mar 23 | James F. Cummings | Common Stock | Grant | Acquire A | No | No | 0 | 90,000 | 0.00 | 238,100 |
| 17 Mar 23 | James F. Cummings | Common Stock | Grant | Acquire A | No | No | 0 | 59,350 | 0.00 | 148,100 |
| 17 Mar 23 | James F. Cummings | Common Stock | Grant | Acquire A | No | No | 0 | 45,000 | 0.00 | 88,750 |
| 17 Mar 23 | James F. Cummings | Stock Option Common Stock | Grant | Acquire A | No | No | 0.78 | 410,000 | 319.80 k | 410,000 |
News
Stocks That Hit 52-Week Lows On Thursday
16 Mar 23
12 Health Care Stocks Moving In Wednesday's After-Market Session
15 Mar 23
Vaxart Q4 EPS $(0.18) Beats $(0.23) Estimate, Sales $22.00K Miss $670.00K Estimate
15 Mar 23
Earnings Scheduled For March 15, 2023
15 Mar 23
Earnings Preview: Vaxart
14 Mar 23
Press releases
Vaxart to Present at World Vaccine Congress Washington 2023 on April 5-6
29 Mar 23
Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus
17 Mar 23
Vaxart Provides Business Update and Full Year 2022 Financial Results
15 Mar 23
Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15
8 Mar 23
Vaxart Doses First Subject in the Phase 2 Clinical Trial of its Bivalent Norovirus Candidate
14 Feb 23